BioCryst Pharmaceuticals, Inc.’s launch numbers for Orladeyo (berotralstat) have beat expectations, and the North Carolina-based firm says its drug – the first oral prophylaxis for hereditary angioedema (HAE) – is on track to eventually become a blockbuster, despite being the eighth HAE drug launched in the US. The product brought in $65.2m during the second quarter of 2022 and the firm increased its full-year sales projection from $250m to a range of $255m-$265m.
[Sidebar#SC146260]







